反应详情

To a solution of 2-amino-5-(piperidin-1-yl)-N-(5-(3-(trifluoromethyl)phenyl)-2H-1,2,4-triazol-3-yl)benzamide (50 mg, 0.12 mmol, 1.00 equiv) in dichloromethane (3 mL) was added pyridine (73 mg, 0.92 mmol, 8.00 equiv) followed by the dropwise addition of a solution of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoyl chloride (54 mg, 0.17 mmol, 1.50 equiv) in dichloromethane (2 mL) and the resulting solution was stirred for 30 min at room temperature. The mixture was diluted with 50 mL of ethyl acetate, washed with 2×20 mL of NH4Cl and 2×20 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum. The crude product (50 mg) was purified by reverse phase HPLC eluting with a water/CH3CN gradient containing 0.05% TFA. The product was obtained as 12 mg (10%) of a yellow solid. 1H-NMR (300 MHz, CD3OD, ppm): δ 8.34(m, 3H), 8.17(t, J=7.8 Hz, 2H), 7.73(m, 5H), 7.42 (m, 1H), 3.98(s, 2H), 3.55(m, 3H), 3.40(m, 5H), 3.29(m, 1H), 3.09(m, 3H), 1.86(d, J=4.8 Hz, 4H), 1.71(t, J=5.1 Hz, 2H). MS (ES, m/z): 705 [M+H]+.

1. washwashed with 2×20 mL of NH4Cl and 2×20 mL of brine
2. dry with materialdried over anhydrous sodium sulfate
3. concentrationconcentrated under vacuum
4. customThe crude product (50 mg) was purified by reverse phase HPLC
5. washeluting with a water/CH3CN gradient
6. additioncontaining 0.05% TFA